<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518180</url>
  </required_header>
  <id_info>
    <org_study_id>V59P18</org_study_id>
    <nct_id>NCT00518180</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents</brief_title>
  <official_title>A Phase 3, Single-Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY Vaccine Administered Either Alone or Concomitantly With a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine in Healthy Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY
      conjugate vaccine when administered with Tdap and HPV vaccinations to healthy adolescents
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Seroresponse</measure>
    <time_frame>1 month post MenACWY vaccination</time_frame>
    <description>Immune responses to MenACWY, as measured by the percentage of hSBA seroresponders, when given: (a) alone; (b) concomitantly with a Tetanus diphtheria acellular pertussis (Tdap) vaccine and a Human Papillomavirus Recombinant (HPV) vaccine; and (c) when given one month after a Tdap vaccine.
Seroresponse to MenACWY: For a subject with baseline hSBA titer &lt;1:4, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with baseline hSBA titer ≥ 1:4, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Antidiphtheria and Antitetanus Toxin ≥1.0 IU/mL</measure>
    <time_frame>1 month post Tdap vaccination</time_frame>
    <description>To compare the immune response to Tdap given concomitantly with MenACWY and HPV vaccine with the immune response to Tdap when administered alone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentrations (GMC) of Antipertussis Toxin (Anti-PT), Antifilamentous Hemagglutinin (Anti-FHA), and Antipertactin (Anti-PRN)</measure>
    <time_frame>1 month post Tdap vaccination</time_frame>
    <description>To compare the immune response of Tdap given concomitantly with MenACWY and HPV vaccine with the immune response of Tdap when administered alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Concomitant and Sequential Vaccination on hSBA Geometric Mean Titers (GMTs) for A, C, W, and Y Serogroups</measure>
    <time_frame>1 month post MenACWY vaccination</time_frame>
    <description>The immune responses to the MenACWY conjugate vaccine, as measured by the hSBA Geometric Mean Titers (GMTs) when given: (a) alone, (b) concomitantly with the Tdap vaccine and the HPV vaccine, and (c) when given one month after the Tdap vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Anti-HPV Seroconversion</measure>
    <time_frame>1 month post third HPV vaccination</time_frame>
    <description>To compare the immune response of HPV vaccine given concomitantly with MenACWY and Tdap to the response when HPV vaccine is given alone. (Immune response against HPV virus-like particles (VLPs) for types 6, 11, 16, and 18 was measured at one month after the third HPV vaccination.) Anti-HPV Seroconversion (SC): SC was defined as negative (baseline HPV titer &lt; type-specific cut-off) for anti-HPV and anti-HPV ≥ an HPV type-specific cut-off at one month after the third HPV injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Anti-HPV by Competitive Luminex Immunoassay</measure>
    <time_frame>1 month post third HPV vaccination</time_frame>
    <description>To compare the immune response of HPV vaccine given concomitantly with MenACWY and Tdap to the response when HPV vaccine is given alone. (Immune response against HPV virus-like particles (VLPs) for types 6, 11, 16, and 18 was measured at one month after the third HPV vaccine vaccination.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With hSBA ≥ 1:8, hSBA Titer ≥ 1:4, for A, C, W, and Y Serogroups</measure>
    <time_frame>1 month post MenACWY vaccination</time_frame>
    <description>The immune responses to MenACWY, as measured by the percentage of subjects with hSBA titer ≥ 1:8, hSBA titer ≥ 1:4, when given: (a) alone, (b) concomitantly with Tdap and HPV vaccine; and (c) when given one month after Tdap.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Effect of Sequential Vaccination on Immunogenicity for Diphtheria and Tetanus</measure>
    <time_frame>1 month post Tdap vaccination</time_frame>
    <description>The immune response to the Tdap vaccine, as measured by the percentage of subjects with antidiphtheria and antitetanus toxin ≥1.0 IU/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus</measure>
    <time_frame>1 month post Tdap vaccination</time_frame>
    <description>To compare the immune response of Tdap, as measured by the antidiphtheria and antitetanus GMCs, when administered one month after the MenACWY vaccine with the immune response of the Tdap vaccine when administered alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT) of Pertussis Antigens</measure>
    <time_frame>1 month post Tdap vaccination</time_frame>
    <description>To compare the immune response to Tdap administered one month after MenACWY with the immune response to Tdap administered alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With at Least a 4-fold Rise for PT, FHA, and PRN</measure>
    <time_frame>1 month post Tdap vaccination</time_frame>
    <description>To compare the immune response of Tdap, defined by the percentage of subjects with a 4-fold rise in antibody titer over baseline against PT, FHA, PRN, when administered one month after the MenACWY with the immune response of Tdap when administered alone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Reactogenicity Sign After MenACWY and Tdap Vaccination.</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Number of subjects with specified local and systemic reactions were assessed when MenACWY was given alone, one month after Tdap, and concomitantly with Tdap and HPV vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Reactogenicity Sign After Each HPV Vaccination</measure>
    <time_frame>Days 1 to 7</time_frame>
    <description>Number of subjects with specified local and systemic reactions were solicited for 7 days after the HPV vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1620</enrollment>
  <condition>Meningococcal Meningitis</condition>
  <condition>Human Papillomavirus Infection</condition>
  <condition>Pertussis</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>MenACWY + Tdap + HPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received MenACWY concomitantly with Tdap and HPV at study month 0 followed by two injections of HPV at month 2 and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY →Tdap → HPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received MenACWY at study month 0 followed by one injection of Tdap at month 1, followed by three injections of HPV at months 2, 4, and 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tdap →MenACWY → HPV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received Tdap at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Meningococcal ACWY Conjugate Vaccine</intervention_name>
    <description>One dose of vaccine administered intramuscularly</description>
    <arm_group_label>MenACWY + Tdap + HPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tdap Vaccine</intervention_name>
    <description>One dose of vaccine administered intramuscularly</description>
    <arm_group_label>Tdap →MenACWY → HPV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Novartis Meningococcal ACWY Conjugate Vaccine</intervention_name>
    <description>One dose of vaccine administered intramuscularly</description>
    <arm_group_label>MenACWY →Tdap → HPV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adolescents 11-18 years of age

          -  virgins (both male and female) with no intention of becoming sexually active during
             the study period

          -  who have been properly vaccinated against diphtheria, tetanus, pertussis

        Exclusion Criteria:

          -  who had a previous confirmed or suspected disease caused by N. meningitidis;

          -  who have previously been immunized with a meningococcal vaccine

          -  who have received prior human papillomavirus (HPV) vaccine;

          -  who have any serious acute, chronic or progressive disease

          -  who have epilepsy, any progressive neurological disease or history of Guillain-Barre
             syndrome;

          -  who have a known or suspected impairment/alteration of immune function, either
             congenital or acquired

          -  who are known to have a bleeding diathesis, or any condition that may be associated
             with a prolonged bleeding time;

          -  who have Down's syndrome or other known cytogenic disorders;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Jose, Costa Rica</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Costa Rica</country>
  </location_countries>
  <results_reference>
    <citation>Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, Grunwald U, Bedell L, Anemona A, Dull PM. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine. 2010 Apr 19;28(18):3171-9. doi: 10.1016/j.vaccine.2010.02.045. Epub 2010 Feb 26.</citation>
    <PMID>20189491</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2007</study_first_submitted>
  <study_first_submitted_qc>August 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <results_first_submitted>March 19, 2010</results_first_submitted>
  <results_first_submitted_qc>September 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2010</results_first_posted>
  <disposition_first_submitted>August 12, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>August 3, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 10, 2009</disposition_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal</keyword>
  <keyword>meningitis</keyword>
  <keyword>vaccine</keyword>
  <keyword>adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at a single center in Costa Rica.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were randomized at a 1:1:1 ratio to receive the MenACWY vaccine when given alone and concomitantly with the Tdap vaccine and the HPV vaccine at different schedules.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenACWY+Tdap+HPV</title>
          <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
        </group>
        <group group_id="P2">
          <title>MenACWY→Tdap→HPV</title>
          <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
        </group>
        <group group_id="P3">
          <title>Tdap →MenACWY → HPV</title>
          <description>Tdap vaccine was administered at month 0 followed by one injection of MenACWY at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="540"/>
                <participants group_id="P2" count="541"/>
                <participants group_id="P3" count="539"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="475"/>
                <participants group_id="P2" count="472"/>
                <participants group_id="P3" count="457"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="82"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenACWY+Tdap+HPV</title>
          <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
        </group>
        <group group_id="B2">
          <title>MenACWY→Tdap→HPV</title>
          <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
        </group>
        <group group_id="B3">
          <title>Tdap →MenACWY → HPV</title>
          <description>Tdap vaccine was administered at month 0 followed by one injection of MenACWY at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="540"/>
            <count group_id="B2" value="541"/>
            <count group_id="B3" value="539"/>
            <count group_id="B4" value="1620"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="2.1"/>
                    <measurement group_id="B2" value="13.9" spread="2.2"/>
                    <measurement group_id="B3" value="13.8" spread="2.2"/>
                    <measurement group_id="B4" value="13.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="307"/>
                    <measurement group_id="B4" value="924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="232"/>
                    <measurement group_id="B4" value="696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="539"/>
                    <measurement group_id="B2" value="541"/>
                    <measurement group_id="B3" value="539"/>
                    <measurement group_id="B4" value="1619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Seroresponse</title>
        <description>Immune responses to MenACWY, as measured by the percentage of hSBA seroresponders, when given: (a) alone; (b) concomitantly with a Tetanus diphtheria acellular pertussis (Tdap) vaccine and a Human Papillomavirus Recombinant (HPV) vaccine; and (c) when given one month after a Tdap vaccine.
Seroresponse to MenACWY: For a subject with baseline hSBA titer &lt;1:4, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with baseline hSBA titer ≥ 1:4, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>1 month post MenACWY vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population. A total of 182 subjects were excluded from the PP population due to protocol deviations. The most common protocol deviations were blood draw performed outside the protocol-specified window.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap→HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
          <group group_id="O3">
            <title>Tdap →MenACWY → HPV</title>
            <description>Tdap vaccine was administered at month 0 followed by one injection of MenACWY at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Seroresponse</title>
          <description>Immune responses to MenACWY, as measured by the percentage of hSBA seroresponders, when given: (a) alone; (b) concomitantly with a Tetanus diphtheria acellular pertussis (Tdap) vaccine and a Human Papillomavirus Recombinant (HPV) vaccine; and (c) when given one month after a Tdap vaccine.
Seroresponse to MenACWY: For a subject with baseline hSBA titer &lt;1:4, seroresponse is defined as a postvaccination hSBA titer ≥ 1:8; for a subject with baseline hSBA titer ≥ 1:4, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
          <population>The analysis was performed on the per-protocol (PP) population. A total of 182 subjects were excluded from the PP population due to protocol deviations. The most common protocol deviations were blood draw performed outside the protocol-specified window.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="487"/>
                <count group_id="O3" value="458"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (N=494, 486, 458)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="76" upper_limit="84"/>
                    <measurement group_id="O2" value="82" lower_limit="78" upper_limit="85"/>
                    <measurement group_id="O3" value="87" lower_limit="83" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=476, 472, 457)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="79" upper_limit="86"/>
                    <measurement group_id="O2" value="84" lower_limit="81" upper_limit="88"/>
                    <measurement group_id="O3" value="84" lower_limit="80" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (N=487, 474, 458)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="73" upper_limit="80"/>
                    <measurement group_id="O2" value="81" lower_limit="77" upper_limit="84"/>
                    <measurement group_id="O3" value="65" lower_limit="61" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=493, 487, 460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="79" upper_limit="86"/>
                    <measurement group_id="O2" value="82" lower_limit="79" upper_limit="86"/>
                    <measurement group_id="O3" value="78" lower_limit="74" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immune response to Men A when MenACWY is administered concomitantly with Tdap and HPV, compared with the immune response to MenACWY when administered alone. Method: ANCOVA. Parameter estimate: Vaccine Group Differences.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immunogenicity of MenACWY given concomitantly with HPV and Tdap was considered non inferior to the immunogenicity of MenACWY administered alone, if, for each serogroup, the lower limit of the two-sided 95% confidence interval (CI) for the difference in percentage of subjects with seroresponse at one month after MenACWY vaccination (PGroup I minus PGroup II) was greater than -10%.</non_inferiority_desc>
            <param_type>Vaccine Group differences (%)</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immune response to Men C when MenACWY is administered concomitantly with Tdap and HPV, compared with the immune response to MenACWY when administered alone. Method: ANCOVA. Parameter estimate: Vaccine Group Differences.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immunogenicity of MenACWY given concomitantly with HPV and Tdap was considered non inferior to the immunogenicity of MenACWY administered alone, if, for each serogroup, the lower limit of the two-sided 95% confidence interval (CI) for the difference in percentage of subjects with seroresponse at one month after MenACWY vaccination (PGroup I minus PGroup II) was greater than -10%.</non_inferiority_desc>
            <param_type>Vaccine Group differences (%)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immune response to Men W when MenACWY is administered concomitantly with Tdap and HPV, compared with the immune response to MenACWY when administered alone. Method: ANCOVA. Parameter estimate: Vaccine Group Differences.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immunogenicity of MenACWY given concomitantly with HPV and Tdap was considered non inferior to the immunogenicity of MenACWY administered alone, if, for each serogroup, the lower limit of the two-sided 95% confidence interval (CI) for the difference in percentage of subjects with seroresponse at one month after MenACWY vaccination (PGroup I minus PGroup II) was greater than -10%.</non_inferiority_desc>
            <param_type>Vaccine Group differences (%)</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Immune response to Men Y when MenACWY is administered concomitantly with Tdap and HPV, compared with the immune response to MenACWY when administered alone. Method: ANCOVA. Parameter estimate: Vaccine Group Differences.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immunogenicity of MenACWY given concomitantly with HPV and Tdap was considered non inferior to the immunogenicity of MenACWY administered alone, if, for each serogroup, the lower limit of the two-sided 95% confidence interval (CI) for the difference in percentage of subjects with seroresponse at one month after MenACWY vaccination (PGroup I minus PGroup II) was greater than -10%.</non_inferiority_desc>
            <param_type>Vaccine Group differences (%)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immune response to Men A when MenACWY is administered 1 month after Tdap, compared with the immune response to MenACWY when administered alone. Method: ANCOVA. Parameter estimate: Vaccine Group Differences.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immunogenicity of MenACWY given after Tdap was considered non inferior to the immunogenicity of MenACWY administered alone, if, for each serogroup, the lower limit of the two-sided 95% confidence interval (CI) for the difference in percentage of subjects with seroresponse at one month after MenACWY vaccination (PGroup III minus PGroup II) was greater than -10%.</non_inferiority_desc>
            <param_type>Vaccine Group differences (%)</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immune response to Men C when MenACWY is administered 1 month after Tdap, compared with the immune response to MenACWY when administered alone. Method: ANCOVA. Parameter estimate: Vaccine Group Differences.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immunogenicity of MenACWY given after Tdap was considered non inferior to the immunogenicity of MenACWY administered alone, if, for each serogroup, the lower limit of the two-sided 95% confidence interval (CI) for the difference in percentage of subjects with seroresponse at one month after MenACWY vaccination (PGroup III minus PGroup II) was greater than -10%.</non_inferiority_desc>
            <param_type>Vaccine Group differences (%)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immune response to Men W when MenACWY is administered 1 month after Tdap, compared with the immune response to MenACWY when administered alone. Method: ANCOVA. Parameter estimate: Vaccine Group Differences.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immunogenicity of MenACWY given after Tdap was considered non inferior to the immunogenicity of MenACWY administered alone, if, for each serogroup, the lower limit of the two-sided 95% confidence interval (CI) for the difference in percentage of subjects with seroresponse at one month after MenACWY vaccination (PGroup III minus PGroup II) was greater than -10%.</non_inferiority_desc>
            <param_type>Vaccine Group differences (%)</param_type>
            <param_value>-16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21</ci_lower_limit>
            <ci_upper_limit>-10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immune response to Men Y when MenACWY is administered 1 month after Tdap, compared with the immune response to MenACWY when administered alone. Method: ANCOVA. Parameter estimate: Vaccine Group Differences.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The immunogenicity of MenACWY given after Tdap was considered non inferior to the immunogenicity of MenACWY administered alone, if, for each serogroup, the lower limit of the two-sided 95% confidence interval (CI) for the difference in percentage of subjects with seroresponse at one month after MenACWY vaccination (PGroup III minus PGroup II) was greater than -10%.</non_inferiority_desc>
            <param_type>Vaccine Group differences (%)</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Antidiphtheria and Antitetanus Toxin ≥1.0 IU/mL</title>
        <description>To compare the immune response to Tdap given concomitantly with MenACWY and HPV vaccine with the immune response to Tdap when administered alone</description>
        <time_frame>1 month post Tdap vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population. A total of 183 subjects were excluded from the PP population due to protocol deviations. The most common protocol deviations were blood draw performed outside the protocol-specified window.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap→HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
          <group group_id="O3">
            <title>Tdap →MenACWY → HPV</title>
            <description>Tdap vaccine was administered at month 0 followed by one injection of MenACWY at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Antidiphtheria and Antitetanus Toxin ≥1.0 IU/mL</title>
          <description>To compare the immune response to Tdap given concomitantly with MenACWY and HPV vaccine with the immune response to Tdap when administered alone</description>
          <population>The analysis was performed on the per-protocol (PP) population. A total of 183 subjects were excluded from the PP population due to protocol deviations. The most common protocol deviations were blood draw performed outside the protocol-specified window.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O3" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non inferiority of the immune response to diphteria antigen, when Tdap is administered concomitantly with MenACWY and HPV, compared with the immune response to Tdap when administered alone. Method: ANCOVA. Parameter estimate: Vaccine Group Differences.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority of the immune response to Tdap when administered concomitantly with MenACWY and HPV, compared with the immune response to Tdap when administered alone, was demonstrated for the diphteria and tetanus antigens if the lower limits of the two-sided 95% CIs around the difference in the percentages of subjects with ELISA anti-D toxin ≥ 1.0 IU/mL [Group I minus Group III] were greater than -10%.</non_inferiority_desc>
            <param_type>Vaccine Group differences (%)</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non inferiority of the immune response to tetanus antigen, when Tdap is administered concomitantly with MenACWY and HPV, compared with the immune response to Tdap when administered alone. Method: ANCOVA. Parameter estimate: Vaccine Group Differences.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non inferiority of the immune response to Tdap when administered concomitantly with MenACWY and HPV, compared with the immune response to Tdap when administered alone, was demonstrated for the diphteria and tetanus antigens if the lower limits of the two-sided 95% CIs around the difference in the percentages of subjects with ELISA anti-D toxin ≥ 1.0 IU/mL [Group I minus Group III] were greater than -10%.</non_inferiority_desc>
            <param_type>Vaccine Group differences (%)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Concomitant and Sequential Vaccination on hSBA Geometric Mean Titers (GMTs) for A, C, W, and Y Serogroups</title>
        <description>The immune responses to the MenACWY conjugate vaccine, as measured by the hSBA Geometric Mean Titers (GMTs) when given: (a) alone, (b) concomitantly with the Tdap vaccine and the HPV vaccine, and (c) when given one month after the Tdap vaccine.</description>
        <time_frame>1 month post MenACWY vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap→HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8</description>
          </group>
          <group group_id="O3">
            <title>Tdap → MenACWY→HPV</title>
            <description>Tdap was administered at study month 0 followed by one injection of the MenACWY vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Concomitant and Sequential Vaccination on hSBA Geometric Mean Titers (GMTs) for A, C, W, and Y Serogroups</title>
          <description>The immune responses to the MenACWY conjugate vaccine, as measured by the hSBA Geometric Mean Titers (GMTs) when given: (a) alone, (b) concomitantly with the Tdap vaccine and the HPV vaccine, and (c) when given one month after the Tdap vaccine.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="494"/>
                <count group_id="O2" value="487"/>
                <count group_id="O3" value="460"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (N=494, 486, 458)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="52" upper_limit="74"/>
                    <measurement group_id="O2" value="67" lower_limit="56" upper_limit="80"/>
                    <measurement group_id="O3" value="95" lower_limit="79" upper_limit="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (N=476, 472, 457)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66" lower_limit="56" upper_limit="77"/>
                    <measurement group_id="O2" value="70" lower_limit="60" upper_limit="83"/>
                    <measurement group_id="O3" value="68" lower_limit="58" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (N=487, 474, 458)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146" lower_limit="129" upper_limit="165"/>
                    <measurement group_id="O2" value="159" lower_limit="140" upper_limit="181"/>
                    <measurement group_id="O3" value="104" lower_limit="91" upper_limit="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (N=493, 487, 460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="62" upper_limit="84"/>
                    <measurement group_id="O2" value="81" lower_limit="70" upper_limit="95"/>
                    <measurement group_id="O3" value="57" lower_limit="49" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Anti-HPV Seroconversion</title>
        <description>To compare the immune response of HPV vaccine given concomitantly with MenACWY and Tdap to the response when HPV vaccine is given alone. (Immune response against HPV virus-like particles (VLPs) for types 6, 11, 16, and 18 was measured at one month after the third HPV vaccination.) Anti-HPV Seroconversion (SC): SC was defined as negative (baseline HPV titer &lt; type-specific cut-off) for anti-HPV and anti-HPV ≥ an HPV type-specific cut-off at one month after the third HPV injection.</description>
        <time_frame>1 month post third HPV vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>HPV Alone</title>
            <description>Three injections of the HPV vaccine were administered at study months 2, 4, and 8. This arm is a recombination of the two arms listed in the Participant Flow.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Anti-HPV Seroconversion</title>
          <description>To compare the immune response of HPV vaccine given concomitantly with MenACWY and Tdap to the response when HPV vaccine is given alone. (Immune response against HPV virus-like particles (VLPs) for types 6, 11, 16, and 18 was measured at one month after the third HPV vaccination.) Anti-HPV Seroconversion (SC): SC was defined as negative (baseline HPV titer &lt; type-specific cut-off) for anti-HPV and anti-HPV ≥ an HPV type-specific cut-off at one month after the third HPV injection.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="744"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 6 (N=361, 737)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 11 (N=362, 744)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 16 (N=360, 744)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 18 (N=364, 743)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) of Anti-HPV by Competitive Luminex Immunoassay</title>
        <description>To compare the immune response of HPV vaccine given concomitantly with MenACWY and Tdap to the response when HPV vaccine is given alone. (Immune response against HPV virus-like particles (VLPs) for types 6, 11, 16, and 18 was measured at one month after the third HPV vaccine vaccination.)</description>
        <time_frame>1 month post third HPV vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>HPV Alone</title>
            <description>The three injections of the HPV vaccine was administered at study months 2, 4, and 8. This arm is a recombination of the two arms listed in the Participant Flow.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Anti-HPV by Competitive Luminex Immunoassay</title>
          <description>To compare the immune response of HPV vaccine given concomitantly with MenACWY and Tdap to the response when HPV vaccine is given alone. (Immune response against HPV virus-like particles (VLPs) for types 6, 11, 16, and 18 was measured at one month after the third HPV vaccine vaccination.)</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="364"/>
                <count group_id="O2" value="745"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV 6 (N=361, 737)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1059" lower_limit="926" upper_limit="1212"/>
                    <measurement group_id="O2" value="1461" lower_limit="1327" upper_limit="1608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 11 (N=362, 744)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1264" lower_limit="1134" upper_limit="1408"/>
                    <measurement group_id="O2" value="1701" lower_limit="1575" upper_limit="1837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 16 (N=360, 744)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5286" lower_limit="4705" upper_limit="5939"/>
                    <measurement group_id="O2" value="6590" lower_limit="6068" upper_limit="7158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV 18 (N=364, 743)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="908" lower_limit="798" upper_limit="1032"/>
                    <measurement group_id="O2" value="1117" lower_limit="1019" upper_limit="1224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With hSBA ≥ 1:8, hSBA Titer ≥ 1:4, for A, C, W, and Y Serogroups</title>
        <description>The immune responses to MenACWY, as measured by the percentage of subjects with hSBA titer ≥ 1:8, hSBA titer ≥ 1:4, when given: (a) alone, (b) concomitantly with Tdap and HPV vaccine; and (c) when given one month after Tdap.</description>
        <time_frame>1 month post MenACWY vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap→HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
          <group group_id="O3">
            <title>Tdap → MenACWY→HPV</title>
            <description>Tdap was administered at study month 0 followed by one injection of the MenACWY vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With hSBA ≥ 1:8, hSBA Titer ≥ 1:4, for A, C, W, and Y Serogroups</title>
          <description>The immune responses to MenACWY, as measured by the percentage of subjects with hSBA titer ≥ 1:8, hSBA titer ≥ 1:4, when given: (a) alone, (b) concomitantly with Tdap and HPV vaccine; and (c) when given one month after Tdap.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="475"/>
                <count group_id="O2" value="472"/>
                <count group_id="O3" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A hSBA ≥ 1:8 (N=494, 486, 458)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="78" upper_limit="85"/>
                    <measurement group_id="O2" value="82" lower_limit="79" upper_limit="86"/>
                    <measurement group_id="O3" value="89" lower_limit="85" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C hSBA ≥ 1:8 (N=476, 472, 457)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="89" upper_limit="94"/>
                    <measurement group_id="O2" value="90" lower_limit="87" upper_limit="93"/>
                    <measurement group_id="O3" value="93" lower_limit="90" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W hSBA ≥ 1:8 (N=487, 474, 458)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="95" lower_limit="93" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y hSBA ≥ 1:8 (N=493, 487, 460)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="90" upper_limit="95"/>
                    <measurement group_id="O2" value="93" lower_limit="90" upper_limit="95"/>
                    <measurement group_id="O3" value="92" lower_limit="90" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A hSBA ≥ 1:4 (N=408, 404, 412)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="79" upper_limit="86"/>
                    <measurement group_id="O2" value="83" lower_limit="79" upper_limit="86"/>
                    <measurement group_id="O3" value="90" lower_limit="87" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C hSBA ≥ 1:4 (N=456, 447, 430)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="90" upper_limit="94"/>
                    <measurement group_id="O2" value="92" lower_limit="89" upper_limit="94"/>
                    <measurement group_id="O3" value="94" lower_limit="92" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W hSBA ≥ 1:4 (N=478, 471, 443)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="97" upper_limit="99"/>
                    <measurement group_id="O2" value="99" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="97" lower_limit="95" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y hSBA ≥ 1:4 (N=465, 456, 438)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="92" upper_limit="96"/>
                    <measurement group_id="O2" value="94" lower_limit="91" upper_limit="96"/>
                    <measurement group_id="O3" value="95" lower_limit="93" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of Sequential Vaccination on Immunogenicity for Diphtheria and Tetanus</title>
        <description>The immune response to the Tdap vaccine, as measured by the percentage of subjects with antidiphtheria and antitetanus toxin ≥1.0 IU/mL.</description>
        <time_frame>1 month post Tdap vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap→HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8</description>
          </group>
          <group group_id="O3">
            <title>Tdap → MenACWY→HPV</title>
            <description>Tdap was administered at study month 0 followed by one injection of the MenACWY vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Sequential Vaccination on Immunogenicity for Diphtheria and Tetanus</title>
          <description>The immune response to the Tdap vaccine, as measured by the percentage of subjects with antidiphtheria and antitetanus toxin ≥1.0 IU/mL.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria (% ≥1.0 IU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O3" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus (% ≥1.0 IU/mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="99" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus</title>
        <description>To compare the immune response of Tdap, as measured by the antidiphtheria and antitetanus GMCs, when administered one month after the MenACWY vaccine with the immune response of the Tdap vaccine when administered alone.</description>
        <time_frame>1 month post Tdap vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap→HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8</description>
          </group>
          <group group_id="O3">
            <title>Tdap → MenACWY→HPV</title>
            <description>Tdap was administered at study month 0 followed by one injection of the MenACWY vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus</title>
          <description>To compare the immune response of Tdap, as measured by the antidiphtheria and antitetanus GMCs, when administered one month after the MenACWY vaccine with the immune response of the Tdap vaccine when administered alone.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" lower_limit="34" upper_limit="41"/>
                    <measurement group_id="O2" value="10" lower_limit="9.12" upper_limit="12"/>
                    <measurement group_id="O3" value="10" lower_limit="9.38" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.75" lower_limit="8.23" upper_limit="9.3"/>
                    <measurement group_id="O2" value="12" lower_limit="11" upper_limit="13"/>
                    <measurement group_id="O3" value="10" lower_limit="9.46" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMT) of Pertussis Antigens</title>
        <description>To compare the immune response to Tdap administered one month after MenACWY with the immune response to Tdap administered alone.</description>
        <time_frame>1 month post Tdap vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap→HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8</description>
          </group>
          <group group_id="O3">
            <title>Tdap → MenACWY→HPV</title>
            <description>Tdap was administered at study month 0 followed by one injection of the MenACWY vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) of Pertussis Antigens</title>
          <description>To compare the immune response to Tdap administered one month after MenACWY with the immune response to Tdap administered alone.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT (N=479, 451, 477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="47" upper_limit="55"/>
                    <measurement group_id="O2" value="79" lower_limit="72" upper_limit="87"/>
                    <measurement group_id="O3" value="63" lower_limit="58" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (N=489, 457, 485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342" lower_limit="310" upper_limit="376"/>
                    <measurement group_id="O2" value="1106" lower_limit="989" upper_limit="1238"/>
                    <measurement group_id="O3" value="511" lower_limit="464" upper_limit="563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN (N=492, 458, 487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="819" lower_limit="727" upper_limit="923"/>
                    <measurement group_id="O2" value="1563" lower_limit="1390" upper_limit="1758"/>
                    <measurement group_id="O3" value="1197" lower_limit="1061" upper_limit="1350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With at Least a 4-fold Rise for PT, FHA, and PRN</title>
        <description>To compare the immune response of Tdap, defined by the percentage of subjects with a 4-fold rise in antibody titer over baseline against PT, FHA, PRN, when administered one month after the MenACWY with the immune response of Tdap when administered alone.</description>
        <time_frame>1 month post Tdap vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap→HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8</description>
          </group>
          <group group_id="O3">
            <title>Tdap → MenACWY→HPV</title>
            <description>Tdap was administered at study month 0 followed by one injection of the MenACWY vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With at Least a 4-fold Rise for PT, FHA, and PRN</title>
          <description>To compare the immune response of Tdap, defined by the percentage of subjects with a 4-fold rise in antibody titer over baseline against PT, FHA, PRN, when administered one month after the MenACWY with the immune response of Tdap when administered alone.</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT (N=479, 451, 477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="79" upper_limit="86"/>
                    <measurement group_id="O2" value="89" lower_limit="86" upper_limit="92"/>
                    <measurement group_id="O3" value="86" lower_limit="83" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (N=489, 457, 485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="63" upper_limit="71"/>
                    <measurement group_id="O2" value="90" lower_limit="87" upper_limit="93"/>
                    <measurement group_id="O3" value="78" lower_limit="74" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN (N=492, 458, 487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="83" upper_limit="89"/>
                    <measurement group_id="O2" value="95" lower_limit="92" upper_limit="97"/>
                    <measurement group_id="O3" value="89" lower_limit="85" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentrations (GMC) of Antipertussis Toxin (Anti-PT), Antifilamentous Hemagglutinin (Anti-FHA), and Antipertactin (Anti-PRN)</title>
        <description>To compare the immune response of Tdap given concomitantly with MenACWY and HPV vaccine with the immune response of Tdap when administered alone</description>
        <time_frame>1 month post Tdap vaccination</time_frame>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap→HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
          <group group_id="O3">
            <title>Tdap →MenACWY → HPV</title>
            <description>Tdap vaccine was administered at month 0 followed by one injection of MenACWY at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMC) of Antipertussis Toxin (Anti-PT), Antifilamentous Hemagglutinin (Anti-FHA), and Antipertactin (Anti-PRN)</title>
          <description>To compare the immune response of Tdap given concomitantly with MenACWY and HPV vaccine with the immune response of Tdap when administered alone</description>
          <population>The analysis was performed on the per-protocol (PP) population.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="492"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-PT (N=479, 451, 477)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="47" upper_limit="55"/>
                    <measurement group_id="O2" value="79" lower_limit="72" upper_limit="87"/>
                    <measurement group_id="O3" value="63" lower_limit="58" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA (N=489, 457, 485)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="342" lower_limit="310" upper_limit="376"/>
                    <measurement group_id="O2" value="1106" lower_limit="989" upper_limit="1238"/>
                    <measurement group_id="O3" value="511" lower_limit="464" upper_limit="563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRN (N=492, 458, 487)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="819" lower_limit="727" upper_limit="923"/>
                    <measurement group_id="O2" value="1563" lower_limit="1390" upper_limit="1758"/>
                    <measurement group_id="O3" value="1197" lower_limit="1061" upper_limit="1350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non inferiority of the immune response to Tdap is administered concomitantly with MenACWY and HPV, compared with the immune response to Tdap when administered alone, for PT antigen. Method: ANCOVA. Parameter estimate: Vaccine Group Ratio.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Tdap concomitant with MenACWY a was considered non inferior to Tdap alone if, for PT, FHA and pertactin, the lower limit of the two-sided 95% CI for the ratio of the GMCs (GMC Group I / GMC Group III) at 1 month after vaccination was &gt; 0.67.</non_inferiority_desc>
            <param_type>Vaccine Group Ratio</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non inferiority of the immune response to Tdap when administered concomitantly with MenACWY and HPV, compared with the immune response to Tdap when administered alone, for PRN antigen. Method: ANCOVA. Parameter estimate: Vaccine Group Ratio.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Tdap concomitant with MenACWY a was considered non inferior to Tdap alone if, for PT, FHA and pertactin, the lower limit of the two-sided 95% CI for the ratio of the GMCs (GMC Group I / GMC Group III) at 1 month after vaccination was &gt; 0.67.</non_inferiority_desc>
            <param_type>Vaccine Group Ratio</param_type>
            <param_value>0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Non inferiority of the immune response to Tdap when administered concomitantly with MenACWY and HPV, compared with the immune response to Tdap when administered alon, for FHA antigen. Method: ANCOVA. Parameter estimate: Vaccine Group Ratio.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Tdap concomitant with MenACWY a was considered non inferior to Tdap alone if, for PT, FHA and pertactin, the lower limit of the two-sided 95% CI for the ratio of the GMCs (GMC Group I / GMC Group III) at 1 month after vaccination was &gt; 0.67.</non_inferiority_desc>
            <param_type>Vaccine Group Ratio</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Reactogenicity Sign After MenACWY and Tdap Vaccination.</title>
        <description>Number of subjects with specified local and systemic reactions were assessed when MenACWY was given alone, one month after Tdap, and concomitantly with Tdap and HPV vaccine.</description>
        <time_frame>Days 1 to 7</time_frame>
        <population>The analysis was performed on the safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two injections of the HPV vaccine at months 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap → HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
          <group group_id="O3">
            <title>Tdap → MenACWY →HPV</title>
            <description>Tdap vaccine was administered at month 0 followed by one injection of MenACWY at month 1, followed by three injections of the HPV vaccine at months 2, 4, and 8.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Reactogenicity Sign After MenACWY and Tdap Vaccination.</title>
          <description>Number of subjects with specified local and systemic reactions were assessed when MenACWY was given alone, one month after Tdap, and concomitantly with Tdap and HPV vaccine.</description>
          <population>The analysis was performed on the safety set.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="540"/>
                <count group_id="O2" value="541"/>
                <count group_id="O3" value="539"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site pain MenACWY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                    <measurement group_id="O2" value="246"/>
                    <measurement group_id="O3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain Tdap</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367"/>
                    <measurement group_id="O2" value="310"/>
                    <measurement group_id="O3" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema MenACWY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema Tdap</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration MenACWY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration Tdap</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="194"/>
                    <measurement group_id="O3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 38°Celsius post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 38°Celsius post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Med. Used post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/Antipyretic Med. Used post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Reactogenicity Sign After Each HPV Vaccination</title>
        <description>Number of subjects with specified local and systemic reactions were solicited for 7 days after the HPV vaccination.</description>
        <time_frame>Days 1 to 7</time_frame>
        <population>The analysis was performed on the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY+Tdap+HPV</title>
            <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two vaccinations of the HPV vaccine at month 2 and 6.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY→Tdap→HPV</title>
            <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdap vaccine at month 1, followed by three injections of the HPV at months 2, 4, and 8</description>
          </group>
          <group group_id="O3">
            <title>Tdap → MenACWY → HPV</title>
            <description>Tdap vaccine was administered at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Reactogenicity Sign After Each HPV Vaccination</title>
          <description>Number of subjects with specified local and systemic reactions were solicited for 7 days after the HPV vaccination.</description>
          <population>The analysis was performed on the safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="540"/>
                <count group_id="O2" value="494"/>
                <count group_id="O3" value="486"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site pain postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="180"/>
                    <measurement group_id="O3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain (N=498, 483, 468) postvac 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="208"/>
                    <measurement group_id="O3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema postvaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration postvaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="227"/>
                    <measurement group_id="O3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38°C) postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed home postvaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills postvaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea postvaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise postvaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia postvaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia postvaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache postvaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash postvaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38°C) postvaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38°C) postvaccination 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 30-day period following each vaccination.</time_frame>
      <desc>Data provided in Other Adverse Events (&gt;5%) were collected during the 7-day period after each vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>MenACWY+Tdap+HPV</title>
          <description>The MenACWY vaccine was administered concomitantly with the Tdap vaccine and the HPV vaccine at study month 0 followed by two vaccinations of the HPV vaccine at month 2 and 6.</description>
        </group>
        <group group_id="E2">
          <title>MenACWY→Tdap→HPV</title>
          <description>The MenACWY vaccine was administered at study month 0 followed by one injection of the Tdpa vaccine at month 1, followed by three injections of the HPV at months 2,4 and 8.</description>
        </group>
        <group group_id="E3">
          <title>Tdap → MenACWY → HPV</title>
          <description>Tdpa was administered at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2,4 and 8.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="541"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>CUSHING'S SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>BEZOAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="541"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>PITUITARY TUMOUR BENIGN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="541"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMORRHAGIC OVARIAN CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>TESTICULAR TORSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>BEHCET'S SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="540"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="541"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="495" subjects_at_risk="540"/>
                <counts group_id="E2" subjects_affected="489" subjects_at_risk="541"/>
                <counts group_id="E3" subjects_affected="482" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="191" subjects_affected="124" subjects_at_risk="540"/>
                <counts group_id="E2" events="255" subjects_affected="133" subjects_at_risk="541"/>
                <counts group_id="E3" events="289" subjects_affected="142" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="131" subjects_affected="100" subjects_at_risk="540"/>
                <counts group_id="E2" events="201" subjects_affected="117" subjects_at_risk="541"/>
                <counts group_id="E3" events="238" subjects_affected="130" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA HPV</sub_title>
                <counts group_id="E1" events="212" subjects_affected="134" subjects_at_risk="540"/>
                <counts group_id="E2" events="147" subjects_affected="105" subjects_at_risk="541"/>
                <counts group_id="E3" events="166" subjects_affected="101" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION HPV</sub_title>
                <counts group_id="E1" events="179" subjects_affected="119" subjects_at_risk="540"/>
                <counts group_id="E2" events="116" subjects_affected="81" subjects_at_risk="541"/>
                <counts group_id="E3" events="134" subjects_affected="85" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN HPV</sub_title>
                <counts group_id="E1" events="778" subjects_affected="387" subjects_at_risk="540"/>
                <counts group_id="E2" events="666" subjects_affected="320" subjects_at_risk="541"/>
                <counts group_id="E3" events="648" subjects_affected="313" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="284" subjects_affected="171" subjects_at_risk="540"/>
                <counts group_id="E2" events="402" subjects_affected="209" subjects_at_risk="541"/>
                <counts group_id="E3" events="428" subjects_affected="194" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="77" subjects_affected="62" subjects_at_risk="540"/>
                <counts group_id="E2" events="129" subjects_affected="88" subjects_at_risk="541"/>
                <counts group_id="E3" events="123" subjects_affected="84" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA MENVEO</sub_title>
                <counts group_id="E1" events="80" subjects_affected="69" subjects_at_risk="540"/>
                <counts group_id="E2" events="68" subjects_affected="66" subjects_at_risk="541"/>
                <counts group_id="E3" events="71" subjects_affected="65" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA Tdap</sub_title>
                <counts group_id="E1" events="93" subjects_affected="78" subjects_at_risk="540"/>
                <counts group_id="E2" events="40" subjects_affected="38" subjects_at_risk="541"/>
                <counts group_id="E3" events="82" subjects_affected="72" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION MENVEO</sub_title>
                <counts group_id="E1" events="76" subjects_affected="68" subjects_at_risk="540"/>
                <counts group_id="E2" events="72" subjects_affected="70" subjects_at_risk="541"/>
                <counts group_id="E3" events="68" subjects_affected="65" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION Tdap</sub_title>
                <counts group_id="E1" events="101" subjects_affected="90" subjects_at_risk="540"/>
                <counts group_id="E2" events="67" subjects_affected="64" subjects_at_risk="541"/>
                <counts group_id="E3" events="125" subjects_affected="110" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN MENVEO</sub_title>
                <counts group_id="E1" events="307" subjects_affected="264" subjects_at_risk="540"/>
                <counts group_id="E2" events="289" subjects_affected="246" subjects_at_risk="541"/>
                <counts group_id="E3" events="266" subjects_affected="239" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN Tdap</sub_title>
                <counts group_id="E1" events="407" subjects_affected="368" subjects_at_risk="540"/>
                <counts group_id="E2" events="343" subjects_affected="310" subjects_at_risk="541"/>
                <counts group_id="E3" events="427" subjects_affected="383" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="188" subjects_affected="119" subjects_at_risk="540"/>
                <counts group_id="E2" events="225" subjects_affected="132" subjects_at_risk="541"/>
                <counts group_id="E3" events="248" subjects_affected="131" subjects_at_risk="539"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="276" subjects_affected="178" subjects_at_risk="540"/>
                <counts group_id="E2" events="339" subjects_affected="187" subjects_at_risk="541"/>
                <counts group_id="E3" events="440" subjects_affected="200" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="519" subjects_affected="260" subjects_at_risk="540"/>
                <counts group_id="E2" events="749" subjects_affected="284" subjects_at_risk="541"/>
                <counts group_id="E3" events="802" subjects_affected="278" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="540"/>
                <counts group_id="E2" events="64" subjects_affected="47" subjects_at_risk="541"/>
                <counts group_id="E3" events="66" subjects_affected="42" subjects_at_risk="539"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccine and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

